BMY Stock Summary and Trading Ideas (Bristol-Myers Squibb Company | NYSE:BMY)

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.

As of April 25, 2024, BMY stock price declined to $47.27 with 1,291,812 million shares trading.

BMY has a beta of 0.35, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.04 to the broad based SPY ETF.

BMY has a market cap of $95.59 billion. This is considered a Large Cap stock.

Last quarter Bristol-Myers Squibb Company reported $11 billion in Revenue and $1.70 earnings per share. This beat revenue expectation by $285 million and exceeded earnings estimates by $.17.

In the last 3 years, BMY stock traded as high as $81.44 and as low as $46.93.

The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, VOO, SCHD, SPY, IVV.

BMY has underperformed the market in the last year with a price return of -29.7% while the SPY ETF gained +22.4%. BMY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.7% and -6.0%, respectively, while the SPY returned +3.0% and -3.1%, respectively.

BMY support price is $48.24 and resistance is $49.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY stock will trade within this expected range on the day.